Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for nondystrophic myotonia has been reported in the published literature.
No approved treatments are currently available for nondystrophic myotonia. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for nondystrophic myotonia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for nondystrophic myotonia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
No clinical trials have been registered for nondystrophic myotonia.
12 publications have been identified in PubMed for nondystrophic myotonia. Research spans Clinical Trial Publication (25%), Review / Meta-Analysis (17%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 3 | 25% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 4:02 PM UTC
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
mexiletine | mexiletine | University of Rochester Medical Center | 2010 | — | Designated |
View trials for nondystrophic myotonia
2 |
17% |
Patient case studies | 2 | 17% |
Disease patterns and progression | 2 | 17% |
Other research | 1 | 8% |
Testing and diagnosis research | 1 | 8% |
Laboratory research | 1 | 8% |
Kinoshita M (2026). [PMID: 41442183](https://pubmed.ncbi.nlm.nih.gov/41442183/). *J Neurophysiol*. [Basic Science / Preclinical]
Wadhwani AR (2025). [PMID: 40127393](https://pubmed.ncbi.nlm.nih.gov/40127393/). *Neurology*. [Case Report / Case Series]
Barrière S (2025). [PMID: 39875220](https://pubmed.ncbi.nlm.nih.gov/39875220/). *Arch Pediatr*. [Clinical Trial Publication]
Asad M (2025). [PMID: 41202340](https://pubmed.ncbi.nlm.nih.gov/41202340/). *Neuromuscul Disord*. [Clinical Trial Publication]
Saltarella I (2025). [PMID: 40183437](https://pubmed.ncbi.nlm.nih.gov/40183437/). *Acta Myol*. [Review / Meta-Analysis]
Krovvidi S (2025). [PMID: 40535402](https://pubmed.ncbi.nlm.nih.gov/40535402/). *Cureus*. [Case Report / Case Series]
Elettreby AM (2024). [PMID: 38403671](https://pubmed.ncbi.nlm.nih.gov/38403671/). *Neurol Sci*. [Review / Meta-Analysis]
Lloyd A (2024). [PMID: 38416296](https://pubmed.ncbi.nlm.nih.gov/38416296/). *Eur J Health Econ*. [Epidemiology / Natural History]
Henzi BC (2024). [PMID: 39304247](https://pubmed.ncbi.nlm.nih.gov/39304247/). *Lancet Neurol*. [Other]
Vivekanandam V (2024). [PMID: 39304240](https://pubmed.ncbi.nlm.nih.gov/39304240/). *Lancet Neurol*. [Clinical Trial Publication]